Evidence map›Paper›PMID 26729200›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response.

Wei-Jing Gong, Ji-Ye Yin, Xiang-Ping Li, Chao Fang, Di Xiao, Wei Zhang, Hong-Hao Zhou, Xi Li, Zhao-Qian Liu

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06544005 (Implication of Long Non-coding RNA HOTTIP Haplotype), which is not on this map. Cited by 94 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 11 pooled it
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06544005 completednot on this mapstarted 2022, after this paper: background citation

Implication of Long Non-coding RNA HOTTIP Haplotype

TypeobservationalSponsorAin Shams UniversityRan2022 to 2024Enrolled198ConditionsHepatocellular Carcinoma
3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 11 syntheses or guidelines pooled it, 166 citations in OpenAlex.

  1. Association BetweenGenetics research · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Review
  13. International journal of molecular sciences · 2026
    Article
  14. Review
  15. Review
  16. The impact of long non-coding RNAJournal of Cancer · 2025
    Article
  17. Article
  18. Single nucleotide variants in lung cancer.Chinese medical journal pulmonary and critical care medicine · 2024
    Review
  19. Review
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Wei-Jing GongDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
Ji-Ye YinDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
Xiang-Ping LiDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
Chao FangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
Di XiaoDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
Wei ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
Hong-Hao ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
Xi LiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China. lixi6931430@126.com.
Zhao-Qian LiuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China. liuzhaoqian63@126.com.
Xiangya Hospital Central South University · CNCentral South University · CNPharmacoGenetics (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) play important roles in carcinogenesis and drug efficacy. Platinum-based chemotherapy is first-line treatment for lung cancer chemotherapy. In this study, we aimed to investigate the association of well-characterized lung cancer lncRNA genetic polymorphisms with the lung cancer susceptibility and platinum-based chemotherapy response. A total of 498 lung cancer patients and 213 healthy controls were recruited in the study. Among them, 467 patients received at least two cycles of platinum-based chemotherapy. Thirteen polymorphisms in HOXA distal transcript antisense RNA (HOTTIP), HOX transcript antisense intergenic RNA (HOTAIR), H19, CDKN2B antisense RNA 1 (ANRIL), colon cancer-associated transcript 2 (CCAT2), metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), and maternally expressed gene 3 (MEG3) genes were genotyped by allele-specific MALDI-TOF mass spectrometry. We found that patients with HOTTIP rs5883064 C allele or rs1859168 A allele had increased lung cancer risk (P = 0.01, P = 0.01, respectively). CCAT2 rs6983267 (P = 0.02, adenocarcinoma) and H19 rs2107425 (P = 0.02, age under 50 years) showed strong relationship with lung cancer susceptibility. CCAT2 rs6983267, H19 rs2839698, MALAT1 rs619586, and HOTAIR rs7958904 were associated with platinum-based chemotherapy response in dominant model ((P = 0.02, P = 0.04, P = 0.04, P = 0.01, respectively). ANRIL rs10120688 (P = 0.02, adenocarcinoma) and rs1333049 (P = 0.04, small-cell lung cancer), H19 rs2107425 (P = 0.02, small-cell lung cancer) and HOTAIR rs1899663 (P = 0.03, male; P = 0.03, smoker) were associated with response to platinum-based chemotherapy. HOTTIP, CCAT2, H19, HOTAIR, MALATI, ANRIL genetic polymorphisms were significantly associated with lung cancer susceptibility or platinum-based chemotherapy response. They may be potential clinical biomarkers to predict lung cancer risk and platinum-based chemotherapy response.

Indexed as

Genetic Predisposition to DiseasePolymorphism, Single NucleotideAllelesAntineoplastic AgentsFemaleGenotypeHumansLung NeoplasmsMaleMiddle AgedOrganoplatinum CompoundsRNA, Long NoncodingSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAntineoplastic AgentsCDKN2B antisense RNA, humanH19 long non-coding RNAHOTAIR long untranslated RNA, humanlong non-coding RNA CCAT2, humanlong noncoding RNA HOTTIP, humanMALAT1 long non-coding RNA, humanOrganoplatinum CompoundsRNA, Long NoncodingLong non-coding RNALung cancerPlatinum-based chemotherapy responsePolymorphismSusceptibility

Identifiers

PMID26729200
OpenAlexW2231496468

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.